Text Size

Ultrasound-Guided Needle Biopsy in the Diagnosis of Malignant Cervical Lymphadenopathies

This study has been completed.
Sponsor:
Information provided by:
Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01384357
First received: June 27, 2011
Last updated: NA
Last verified: May 2011
History: No changes posted
  Purpose

The objective of the present study was to compare ultrasound (US) characteristics and ultrasound-guided core-needle biopsy (US-CNB) with US-guided fine-needle aspiration (US-FNA) in the assessment of different malignant cervical lymphadenopathies. Patients with malignant cervical lymphadenopathie with either US-FNA or US-CNB over a 3-year period from 2007 July to 2010 Dec were retrospectively reviewed. There are two major study groups according to the treatment status of the patient's population, including patients who had pathology proofed previous cancer and with clinically cervical lymphadenopathies after treatment. The second group included patients with cervical lymphaenopathies but without previous diagnosis of malignancy and treatment. The results of cytology, or pathology and time of needle biopsy to final diagnosis were traced and recorded. Morphologic US parameters and vascular features were thoroughly evaluated and compared in different disease.


Condition
Lymphadenopathy
Malignancy

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Real-time Ultrasound-Guided Needle Biopsy in the Diagnosis of Malignant Cervical Lymphadenopathies

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Far Eastern Memorial Hospital:

Primary Outcome Measures:
  • time of needle biopsy to final diagnosis [ Time Frame: days from needle biopsy to final diagnosis ] [ Designated as safety issue: No ]

Enrollment: 116
Study Start Date: July 2007
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
ultrasound,lymphadenopathy

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   20 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with malignant cervical lymphadenopathie with either US-FNA or US-CNB over a 3-year period from 2007 July to 2010 Dec were retrospectively reviewed. There are two major study groups according to the treatment status of the patient's population, including patients who had pathology proofed previous cancer and with clinically cervical lymphadenopathies after treatment. The second group included patients with cervical lymphaenopathies but without previous diagnosis of malignancy and treatment.

Criteria

Inclusion Criteria:

Patients with malignant cervical lymphadenopathie With US-FNA or US-CNB evaluation before

Exclusion Criteria:

No ultrasound exam

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01384357

Locations
Taiwan
Department of Otolaryngology, Far Eastern Memorial Hospital
Taipei, Taiwan
Sponsors and Collaborators
Far Eastern Memorial Hospital
Investigators
Principal Investigator: Li-Jen Liao, M.D. Department of Otolaryngology, Far Eastern Memorial Hospital, New Taipei City, Taiwan
  More Information

No publications provided

Responsible Party: Liao Li-Jen, Department of Otolaryngology, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier: NCT01384357     History of Changes
Other Study ID Numbers: 100026-E
Study First Received: June 27, 2011
Last Updated: June 27, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by Far Eastern Memorial Hospital:
lymphadenopathy
needle biopsy
sonography

Additional relevant MeSH terms:
Neoplasms
Lymphatic Diseases

ClinicalTrials.gov processed this record on June 17, 2013